Preventive effects of chrysin on the development of azoxymethane-induced colonic aberrant crypt foci in rats. 2006

Shingo Miyamoto, and Hiroyuki Kohno, and Rikako Suzuki, and Shigeyuki Sugie, and Akira Murakami, and Hajime Ohigashi, and Takuji Tanaka
Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan. shingo7@kanazawa-med.ac.jp

The modifying effects of dietary feeding with chrysin (5,7-dihydroxyflavone) on the development of azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) were investigated in male F344 rats. We also assessed the effect of chrysin on mitosis and apoptosis in 'normal appearing' crypts. To induce ACF, rats were given two weekly subcutaneous injections of AOM (20 mg/kg body weight). They also received an experimental diet containing chrysin (0.001 or 0.01%) for 4 weeks, starting 1 week before the first dose of AOM. AOM exposure produced a substantial number of ACF (73+/-13/rat) at the end of the study (week 4). Dietary administration of chrysin caused significant reduction in the frequency of ACF: 0.001% chrysin, 37+/-17/rat (49% reduction, P<0.001); and 0.01% chrysin, 40+/-10/rat (45% reduction, P<0.001). In addition, chrysin administration significantly reduced the mitotic index and significantly increased the apoptotic index in 'normal appearing' crypts. These findings might suggest a possible chemopreventive activity of chrysin in the early step of colon tumorigenesis through modulation of cryptal cell proliferation activity and apoptosis.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008938 Mitosis A type of CELL NUCLEUS division by means of which the two daughter nuclei normally receive identical complements of the number of CHROMOSOMES of the somatic cells of the species. M Phase, Mitotic,Mitotic M Phase,M Phases, Mitotic,Mitoses,Mitotic M Phases,Phase, Mitotic M,Phases, Mitotic M
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004032 Diet Regular course of eating and drinking adopted by a person or animal. Diets
D005419 Flavonoids A group of phenyl benzopyrans named for having structures like FLAVONES. 2-Phenyl-Benzopyran,2-Phenyl-Chromene,Bioflavonoid,Bioflavonoids,Flavonoid,2-Phenyl-Benzopyrans,2-Phenyl-Chromenes,2 Phenyl Benzopyran,2 Phenyl Benzopyrans,2 Phenyl Chromene,2 Phenyl Chromenes
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

Shingo Miyamoto, and Hiroyuki Kohno, and Rikako Suzuki, and Shigeyuki Sugie, and Akira Murakami, and Hajime Ohigashi, and Takuji Tanaka
January 2013, Nutrition and cancer,
Shingo Miyamoto, and Hiroyuki Kohno, and Rikako Suzuki, and Shigeyuki Sugie, and Akira Murakami, and Hajime Ohigashi, and Takuji Tanaka
February 1996, Carcinogenesis,
Shingo Miyamoto, and Hiroyuki Kohno, and Rikako Suzuki, and Shigeyuki Sugie, and Akira Murakami, and Hajime Ohigashi, and Takuji Tanaka
January 1998, Nutrition and cancer,
Shingo Miyamoto, and Hiroyuki Kohno, and Rikako Suzuki, and Shigeyuki Sugie, and Akira Murakami, and Hajime Ohigashi, and Takuji Tanaka
March 1995, Cancer research,
Shingo Miyamoto, and Hiroyuki Kohno, and Rikako Suzuki, and Shigeyuki Sugie, and Akira Murakami, and Hajime Ohigashi, and Takuji Tanaka
February 2002, Japanese journal of cancer research : Gann,
Shingo Miyamoto, and Hiroyuki Kohno, and Rikako Suzuki, and Shigeyuki Sugie, and Akira Murakami, and Hajime Ohigashi, and Takuji Tanaka
March 1997, Carcinogenesis,
Shingo Miyamoto, and Hiroyuki Kohno, and Rikako Suzuki, and Shigeyuki Sugie, and Akira Murakami, and Hajime Ohigashi, and Takuji Tanaka
May 1999, Carcinogenesis,
Shingo Miyamoto, and Hiroyuki Kohno, and Rikako Suzuki, and Shigeyuki Sugie, and Akira Murakami, and Hajime Ohigashi, and Takuji Tanaka
July 2001, Life sciences,
Shingo Miyamoto, and Hiroyuki Kohno, and Rikako Suzuki, and Shigeyuki Sugie, and Akira Murakami, and Hajime Ohigashi, and Takuji Tanaka
July 2004, Cancer letters,
Shingo Miyamoto, and Hiroyuki Kohno, and Rikako Suzuki, and Shigeyuki Sugie, and Akira Murakami, and Hajime Ohigashi, and Takuji Tanaka
January 2006, Nutrition and cancer,
Copied contents to your clipboard!